BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 23, 2026
Home » Newsletters » BioWorld

BioWorld

April 8, 2026

View Archived Issues
Blue digital dollar sign

Sidewinder’s bispecific ADC approach draws $137M series B

Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027. Read More
Varipulse Pro catheter

J&J introduces Varipulse Pro to Europe after CE mark

Johnson & Johnson launched its latest pulsed field ablation (PFA) catheter, Varipulse Pro, in Europe following CE mark approval, bringing another option to electrophysiologists looking to adopt PFA technology. The system features a new pulse sequence with a lower temperature profile and enables ablation that is five times faster than the previous sequence, while achieving equivalent lesions. It represents another significant development in the rapidly evolving PFA market that has transformed cardiac ablation treatment.

Read More
British and U.S. flags

UK formalizes zero tariffs deal with US, will pay more for drugs

The U.S. confirmed the agreement in principle made last December to exempt U.K. pharmaceuticals from import tariffs, as the U.K government put its commitment to spend more on patented drugs into effect. Read More
Illustration of Wnt signaling pathway

Merck Wnt first, Surrozen goes next in AMD, DME

As advances are made by bustling drug developers at work in the Wingless-related integration site (Wnt) pathway, other research is yielding new discoveries as well. Among the closely watched industry players in Wnt are Boehringer Ingelheim GmbH, Merck & Co. Inc., and Surrozen Inc. Read More
Multicolor peptide illustration

New China biotech Syneron chases macrocycle frontier

Syneron Bio is emerging as one of the most heavily backed new entrants in the macrocyclic peptide space, raising more than $250 million in venture funding and securing a multibillion-dollar deal with Astrazeneca plc as it builds a platform spanning several of the most competitive frontiers in drug development. Read More

Ubl to step down from PhRMA

After more than a decade at the helm of the Pharmaceutical Research and Manufacturers of America (PhRMA), Stephen Ubl said he plans to step down as president and CEO of the trade organization at the end of the year. Read More
Eye anatomy and contact lens

Smart contact lens delivers adaptative glaucoma therapy

A smart polymer contact lens measures intraocular pressure (IOP) in real time and automatically releases medication into the eye when IOP goes beyond a critical limit. This technological advance, developed by scientists at the Terasaki Institute for Biomedical Innovation, could enable personalized glaucoma therapy. Read More

Best of BioWorld: Q1

A selection of top news from January through March 2026. Read More

Appointments and advancements for April 8, 2026

New hires and promotions in the biopharma and med-tech industries, including: Abeona, Avicanna, Biovica, Cytovale, Helio Genomics, Jupiter, Lytix, Palvella, Pharmability, Tenpoint, Trisalus, Tuhura, Zimmer. Read More

Financings for April 8, 2026

Biopharma and med-tech companies raising money in public or private financings, including: Celldex, Ensysce, Kiora, Marvel, Polyrizon, Route 92, Transcode, Vivos. Read More

In the clinic for April 8, 2026

Clinical updates for biopharma and med tech, including data readouts and publications: Akeso, Evaxion,Merakris, Neurotherapia, Sanofi. Read More

Other news to note for April 8, 2026

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: AC Immune, Alloy, Amgen, Biocon, Biogen, Caryhealth, Cipher, Cellution, Cipher, Eli Lilly, Engene, Gatc, Halozyme, Lunai, Medstar, Merck, Pathai, Renovare, Vertex, Terns.

Read More

Regulatory actions for April 8, 2026

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Artivion, Ascendis, Baylis, Climb Bio, Invera, Neuropacs, Nextcure, Nuvalent, NX Development, Organogenesis, Outlook, Royal Biologics, Savara. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 22, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing